The acquisition positions Walgreens as one of the largest home infusion therapy providers in US and expands its respiratory therapy and durable medical equipment services.
Option Care services are used by patients with acute or chronic conditions that can be treated at home, in a physician’s office or at any one of OptionCare’s ambulatory infusion sites.
Stanley Blaylock, Walgreens Health Services vice president of specialty pharmacy and home care, said: “Our increased resources instantly expand ability to provide patients and payors with national access to these services. Providing service in this expanding space will help members, payor clients and referral sources to better manage patients’ conditions, their care and the associated costs. This also expands opportunities to gain greater access to limited-distribution biotech medications for clients and patients.”
Paul Mastrapa, president of OptionCare, said: “Both companies are very clinically focused and make a strong cultural fit. With more than 25 years of experience in providing home care services, both organizations are leaders in the health care industry and have established providers with dedicated management and staff who believe we can help our patients live better lives.”
Mr Blaylock added: “The acquisition is another step toward positioning ourselves as a provider of a variety of patient-focused healthcare services. We’re moving beyond traditional pharmacy in ways that are beneficial to patients and help payors better manage their overall medical and pharmacy spending.”